RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Researchers for Sinovac (SVA) indicate in an interview with Sky News that they are “99%” sure that their COVID-19 vaccine candidate will be effective against the coronavirus.
Their vaccine is in Stage 2, with an intent to move into Stage 3 with a trial in the U.K., the report indicates, with the scientists at the Beijing-based company providing assurances of its success.
An investor could view the commentary as aspirational, rather than official commentary, after the scientist responded that “it must be successful” when asked if it would be, and that he was “99%” sure it could be.
Note preclinical trials earlier this month in mice, rats and rhesus macaques showed that the company’s treatment was safe and provided complete protection against SARS-CoV-2 strains (in the primates), according to the SVA Chairman Weidong Yin.
The company also teamed up with Dynavax (DVAX +16.6%) in April on development.
Selected COVID-19 vaccine-related tickers: Vir Biotechnology (VIR +2.8%), Novavax (NVAX -0.2%), Inovio Pharmaceuticals (INO +3.5%), Vaxart (VXRT -2.6%), iBio (IBIO -2.8%), Johnson & Johnson (JNJ -0.6%), Sanofi (SNY -0.5%), GlaxoSmithKline (GSK -0.4%), Pfizer (PFE -1.1%), Soligenix (SNGX -3.4%), AstraZeneca (AZN -0.4%), Arcturus Therapeutics (ARCT -1.4%), GeoVax Labs (OTCPK:GOVX +5.4%), BioNTech (BNTX +3.7%), Altimmune (ALT +10.0%)
